The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections
Abstract
Daptomycin is the first available agent from a new class of antibiotics, the cyclic lipopeptides, that has activity against a broad range of gram-positive pathogens, including organisms that are resistant to methicillin, vancomycin, and other currently available agents. Daptomycin (4 mg/kg intravenously [iv] every 24 h for 7-14 days) was compared with conventional antibiotics (penicillinase-resistant penicillins [4-12 g iv per day] or vancomycin [1 g iv every 12 h]) in 2 randomized, international trials involving 1092 patients with complicated skin and skin-structure infections. Among 902 clinically evaluable patients, clinical success rates were 83.4% and 84.2% for the daptomycin- and comparator-treated groups, respectively (95% confidence interval, -4.0 to 5.6). Among patients successfully treated with iv daptomycin, 63% required only 4-7 days of therapy, compared with 33% of comparator-treated patients (P<.0001). The frequency and distribution of adverse events were similar among both treatment groups. Overall, the safety and efficacy of daptomycin were comparable with conventional therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/345476 · Cited by 1,964
Engemann, J. J., Carmeli, Y., Cosgrove, S. E., Fowler, V. G., Bronstein, M. Z., Trivette, S. L., Briggs, J. P., Sexton, D. J., & Kaye, K. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367653 · Cited by 934
(2001) · American Journal of Infection Control · doi:10.1067/mic.2001.119952 · Cited by 559
Pfaller, M. A., Jones, R. N., Doern, G. V., Kugler, K., & Group, T. S. P. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1762 · Cited by 539
Blot, S. I., Vandewoude, K. H., Hoste, E. A., & Colardyn, F. A. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.19.2229 · Cited by 463
Graffunder, E. M. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf009 · Cited by 411
Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus
Tenover, F. C., Biddle, J. W., & Lancaster, M. V. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010237 · Cited by 391
Rybak, M. J., Hershberger, E., Moldovan, T., & Grucz, R. G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1062-1066.2000 · Cited by 362
Dvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1318-1323.2003 · Cited by 358
Self-citationThrombocytopenia Associated with Linezolid Therapy
Attassi, K., Hershberger, E., Alam, R., & Zervos, M. J. (2002) · Clinical Infectious Diseases · doi:10.1086/338403 · Cited by 259
Stevens, D. L., Smith, L. G., Bruss, J. B., McConnell-Martin, M. A., Duvall, S. E., Todd, W. M., & Hafkin, B. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3408-3413.2000 · Cited by 242
Resistance Studies with Daptomycin
Silverman, J. A., Oliver, N., Andrew, T., & Li, T. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1799-1802.2001 · Cited by 234
Daptomycin disrupts membrane potential in growing Staphylococcus aureus
Alborn, W. E., Allen, N. E., & Preston, D. A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.11.2282 · Cited by 213
Daptomycin: a novel agent for Gram-positive infections
Tally, F. P., Zeckel, M., Wasilewski, M. M., Carini, C., Berman, C. L., Drusano, G. L., & Oleson JR, F. B. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.8.1223 · Cited by 205
Self-citationOnce-Daily Dosing in Dogs Optimizes Daptomycin Safety
Oleson, F. B., Berman, C. L., Kirkpatrick, J. B., Regan, K. S., Lai, J.-J., & Tally, F. P. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.11.2948-2953.2000 · Cited by 196
Self-citationNichols, R. L., Graham, D. R., Barriere, S. L., Rodgers, A., Wilson, S. E., Zervos, M., Dunn, D. L., & Kreter, B. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.2.263 · Cited by 177
Canepari, P., Boaretti, M., Lleò, M. M., & Satta, G. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.6.1220 · Cited by 166
Barry, A. L., FUCHS, P. C., & Brown, S. D. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1919-1922.2001 · Cited by 158
Doern, G. V., Jones, R. N., Pfaller, M. A., Kugler, K. C., & Beach, M. L. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00162-x · Cited by 140
Lamp, K. C., Rybak, M. J., Bailey, E. M., & Kaatz, G. W. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2709 · Cited by 131
The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates
King, A. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.2.219 · Cited by 101
Snydman, D. R., Jacobus, N. V., McDermott, L. A., Lonks, J. R., & Boyce, J. M. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3447-3450.2000 · Cited by 101
Safety and tolerability of quinupristin/dalfopristin: administration guidelines
Rubinstein, E., Prokocimer, P., & Talbot, G. H. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.suppl_1.37 · Cited by 98
Wise, R. A. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.4.563 · Cited by 71
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Stevens, D. L., Bisno, A. L., Chambers, H. F., Dellinger, E. P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, S. L., Montoya, J. G., & Wade, J. C. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu296 · Cited by 2,780
Waves of resistance: Staphylococcus aureus in the antibiotic era
Chambers, H. F., & DeLeo, F. R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2200 · Cited by 2,718
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
Turner, N. A., Sharma-Kuinkel, B. K., Maskarinec, S. A., Eichenberger, E. M., Shah, P. P., Carugati, M., Holland, T. L., & Fowler, V. G. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0147-4 · Cited by 2,051
Metadata
- Authors
- Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06-15
- Volume
- 38
- Issue
- 12
- Pages
- 1673-1681
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2099481682
- Cited by
- 689
- References
- 25
- FWCI
- 31.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.